Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Compound Enhances Skeletal Tissue Regeneration

By BiotechDaily International staff writers
Posted on 08 Apr 2013
New cutting-edge research revealed how a novel low-molecular-weight compound enhances ectopic bone formation and fracture repair.

The study, by investigators from conducted by the Atlanta Veterans Affairs Medical Center (GA, USA) and Emory University School of Medicine (Atlanta, GA, USA), was conducted to design and evaluate small molecules that could enhance recombinant human bone morphogenetic protein-2 (rhBMP-2) responsiveness. The investigation used two models to assess the ability of a small synthetic molecule to optimize bone formation in a rodent ectopic model and to determine whether an injection of that molecule accelerate callus formation in a rodent femoral fracture model.

The findings revealed that a single dose of the small molecule enhanced bone healing in the ectopic model combined with the occurrence of low-dose exogenous rhBMP-2, and in the femoral fracture model with the presence of only naturally occurring BMPs. The study’s findings, published in March 6, 2013, in the Journal of Bone and Joint Surgery.

SkelRegen, LLC (West Chester, PA, USA) is the first company to focus on newly identified small molecules that target different aspects of the skeletal tissue formation pathway. The study’s findings serves as additional confirmation that by following established procedures, SkelRegen continues to work on research to regenerate bone from scratch. “While our work on skeletal tissue regeneration is far from complete, this study exemplifies that research is continuing and SkelRegen technology is at the forefront,” said Stephen LaNeve, SkelRegen’s cofounder and CEO. “Our partnership with Emory University makes it possible for us to be part of such revolutionary work.”

Boden, SkelRegen’s cofounder and chief medical, science and technology officer, said, “The process was long and arduous and would not have been possible without the computational design work of the Emory/VA team led by Sree Sangadala, PhD But, ultimately these results further demonstrate how bone regeneration with small molecules will transform musculoskeletal care.”

SkelRegen identified not one, but multiple small molecules that are osteoinductive and target different features of the skeletal tissue formation pathway. All of the compounds are inexpensive to manufacture and many of the compounds are clear for other uses by the US Food and Drug Administration (FDA), therefore, they already have acceptable safety and toxicity profiles.

Related Links:

Atlanta Veterans Affairs Medical Center
Emory University School of Medicine
Regen



Channels

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.